Registrarme Olvidé mi contraseña /

© 2018 Ciencia IMSS

Nivel III

Nivel
SNI

Titular D

Calificación
Curricular

Lineas de Interés
Centro de Investigación
Investigador
Publicaciones


Dra. Luisa Constanza del Rocío Cervantes Barragán.

Sitio web

Dra. Cristina del Carmen Gil Cruz

Sitio web

Dr. Christian Pérez Shibayama

Sitio web

Paul Klenerman

Sitio web

Adam Cunningham

Sitio web

Burkhard Ludewig

Sitio web

Denis Leclerc

Sitio web

BactiVac

Sitio web

Dr. Natalia Martin-Orozco

Sitio web

Prof. Rodolfo Pastelin-Palacios

Sitio web

How Salmonella infection can inform on mechanisms of immune Function and Homeostasis.

How Salmonella infection can inform on mechanisms of immune Function and Homeostasis. In collaboration with Prof. Adam Cunningham University of Birmingham UK. MoU signed IMSS-University of Birmingham

Development of an oral multivalent vaccine against Salmonella infection.

Development of an oral multivalent vaccine against Salmonella infection. In collaboration with Prof. Burkhard Ludewig. Saint Gallen Kantonal Hospital. Saint Gallen Switzerland.

Characterisation of T and B cell responses to Salmonella porins in humans.

In collaboration with Paul Klenerman, University of Oxford. MoU signed IMSS-Nuffield Department of Medicine, University of Oxford.

Subversion of innate and adaptive immune activation induced by outher membrane molecules from Salmonella.

Subversion of innate and adaptive immune activation induced by outher membrane molecules from Salmonella. In collaboration with Prof. Rodolfo Pastelin. National Autonomous University of Mexico.

Development of adjuvant platforms using plant viruses

Development of adjuvant platforms using plant viruses. With Prof. Denis Leclerc. Laval University. Canada.

Development of a COVID-19 Vaccine Using the Stabilized Spike Protein of the Virus Expressed in the Newcastle Disease Virus LaSota Vector

The vaccine was developed in collaboration with the Mexican company AVIMEX and the Icahn School of Medicine at Mount Sinai in New York City, USA. It successfully completed preclinical trials in mice, hamsters, and pigs. Phase 1, 2, and 3 clinical trials confirmed that the vaccine is safe, well-tolerated, and immunogenic in volunteers. Moreover, its ability to induce neutralizing antibodies was found to be comparable to the ChAdOx-1-S vaccine by AstraZeneca. Finally, AVIMEX established a manufacturing facility, and the vaccine received approval from COFEPRIS (the Federal Commission for Protection Against Sanitary Risks) for use in adults in Mexico

Designing Adjuvants and Immunomodulators with Bacterial Antigens for Vaccines and Cancer Therapy

Purified bacterial antigens are being investigated for their potential to enhance both innate and adaptive immune responses in vaccine formulations. Additionally, these antigens are being studied as adjuvants in cancer immunotherapy, aiming to boost the effectiveness of treatments by modulating the immune system to target tumors more effectively

A multivalent porin mRNA vaccine against diseases caused by Salmonella

An mRNA vaccine utilizing porins is being designed to create a multivalent vaccine targeting diseases caused by bacteria of the genus Salmonella. This project is being conducted in collaboration with Dr. Natalia Martin-Orozco from Providence, a Canadian company

  • Doctorado 2001
    UNAM ETH Universidad de Zurich

  • Maestría 1995
    UNAM Facultad de Médicina

  • Licenciatura 1992
    UNAM Facultad de Química

Dr. López Macías C.


Doctorado
Ciencias Biomédicas

Líneas de investigación:

Adjuvants, Immunologic Bacterial Vaccines Inflammation Influenza Vaccines Salmonella Porins Salmonella Vaccines COVID-19

Ligas de interés

Política de privacidad